MGD020 +/- MGD014 in HIV-1

Phase 1, open-label trial of MGD020 in human immunodeficiency virus type 1 infection (HIV-1) (9 arms), sponsored by MacroGenics. Primary endpoints: Number and Types of Adverse Events (AEs), Including Serious Adverse Events (SAEs), and AEs Leading to Treatment Discontinuation in Participants Receiving MGD020 Alone in Part 1A up to 43 days, Number and Types of AEs, Including SAEs, and AEs Leading to Treatment Discontinuation in Participants Receiving MGD020 and MGD014 in Part 1B up to 43 days and 1 more. Started Sep 2022; status: completed.